1Adamopoulos S,Parissis JT,Georgiadis M,et al.Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas Ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy[J].Am
2Lindsey ML,Gannon J,Aikawa M,et al.Seletive matrix metalloproteinase inhibition reduces left ventricular remodeling,but does not inhibit angiogenesis after myocardial infarction [J].Circulation,2002,105(6):753-758.
3Adamopoulos S,Parissis JT,Karatzas D,et al.Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas Ligand system in patients with chronic heart failure [J].J Am Coll Cardiol,2002,39(4):653-663.
4William B.White.Cyclooxygenase-2 inhibitor and cardiovascular thromboembolic events [J].J Am Coll Cardiol,2002,40(3):577-578.
5Mabuchi N,Tsutumoto T,Wada A,et al.Relationship between interleukin-6 production in the lungs and pulmonary vascular resistance in patients with congestive hear failure [J].Chest,2002,121(4):1195-1202.
6Raul A,Hector L,Juan M,et al.Efficacy assessment of meloxicam,a preferential cyclooxygenase-2 inhibitor,in acute coronary syndromes without ST-segment elevation [J].Circulation,2002,106(2):191-195.
7Bertram P,Carl P,James TW.Cyclooxygenase-2 inhibitor and cardiovascular events[J].Circulation,2002,106(2):167-169.
8Wayne AR,Michael C,James R,et al.COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease [J].Lancet,2002,360(5):1071-1073.
9Helen Frankish.Why do COX-2 inhibitors increase risk of cardiovascular events[J].Lancet,2002,359(20):1410.
10Chancey AL,Brower GL,Peterson JT,et al.Effects of matrix metalloproteinase inhibition in ventricular remodeling due to volume overload [J].Circulation,2002,105(16):1983-1988.
